Product Information
CITALOPRAM HBR 30 MG CAPSULE is a generic product labeled by Almatica Pharma LLC, priced at $4.7700 per EA under NDC 52427069130. Its NADAC has been published 181 times since Apr 19, 2023.
FDA first approved this application on Jan 31, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the citalopram market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
30 mg/1
Manufacturer
Almatica Pharma LLCNDC
52427069130
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CITALOPRAM HYDROBROMIDEApproval Type
New Drug (NDA)
FDA Application
NDA215428FDA Approved
1/31/2022
TE Code
AB
On Market Since
1/31/2022
Pharmacological Classes
Price Statistics
The NADAC for CITALOPRAM HBR 30 MG CAPSULE has been published 181 times since Apr 19, 2023, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.7700 per EA |
|---|---|
| All-time high | $5.1724 (Feb 12, 2025) |
| All-time low | $4.6839 (Apr 19, 2023) |
| 52-week high | $5.1715 |
| 52-week low | $4.7700 |
| Median price | $5.0509 |
| Average price | $5.0111 |
| Largest weekly change | +5.1% (Oct 18, 2023) |
| Weeks tracked | 181 |
| Tracking since | Apr 19, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the citalopram market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Almatica Pharma LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
citalopram market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CITALOPRAM HBR 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CITALOPRAM HBR 30 MG CAPSULE, manufactured by Almatica Pharma LLC, is $4.7700 per EA (NDC 52427069130), effective Sep 30, 2026.
How has the price of CITALOPRAM HBR 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CITALOPRAM HBR 30 MG CAPSULE has held within roughly two percent of its current level. It has been tracked across 181 weekly CMS publications since Apr 19, 2023.
What are the highest and lowest recorded NADAC prices for CITALOPRAM HBR 30 MG CAPSULE?
Since Apr 19, 2023, the NADAC for CITALOPRAM HBR 30 MG CAPSULE has ranged from a low of $4.6839 (Apr 19, 2023) to a high of $5.1724 (Feb 12, 2025), with a median of $5.0509 per EA.
Are there cheaper alternatives to CITALOPRAM HBR 30 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of CITALOPRAM HBR 30 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CITALOPRAM HBR 30 MG CAPSULE?
CITALOPRAM HBR 30 MG CAPSULE (NDC 52427069130) is labeled by Almatica Pharma LLC, and CMS classifies it as a generic product.